223 related articles for article (PubMed ID: 22744885)
21. Issues in noninferiority trials: the evidence in community-acquired pneumonia.
Fleming TR; Powers JH
Clin Infect Dis; 2008 Dec; 47 Suppl 3(Suppl 3):S108-20. PubMed ID: 18986275
[TBL] [Abstract][Full Text] [Related]
22. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
23. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
24. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
Itani KM; Shorr AF
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
[TBL] [Abstract][Full Text] [Related]
25. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
[TBL] [Abstract][Full Text] [Related]
26. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
DeBellis HF; Jones MC; Kincaid SE
J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389
[TBL] [Abstract][Full Text] [Related]
27. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
[No Abstract] [Full Text] [Related]
28. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
29. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
30. Solithromycin: A novel ketolide antibiotic.
Buege MJ; Brown JE; Aitken SL
Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
[TBL] [Abstract][Full Text] [Related]
31. [Tigecycline: a systematic review of clinical experience during first years of prescription].
Diomedi P A
Rev Chilena Infectol; 2009 Apr; 26(2):114-25. PubMed ID: 19621142
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
Lodise TP; Gunter K; Mu F; Gao E; Yang D; Yim E; Sandor S; Berman G
J Manag Care Spec Pharm; 2023 Aug; 29(8):952-964. PubMed ID: 37307087
[No Abstract] [Full Text] [Related]
33. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
34. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
35. Fluoroquinolones in the management of community-acquired pneumonia.
Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacogenetics of community-acquired pneumonia].
Suleĭmanov SSh; Molchanova OV; Kirpichnikova NV; Sukhotina NV; Gorbach AA
Antibiot Khimioter; 2010; 55(9-10):42-4. PubMed ID: 21400754
[TBL] [Abstract][Full Text] [Related]
37. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Vacalis S; Brunton S; Gindi J
J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
[TBL] [Abstract][Full Text] [Related]
38. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
39. Ceftaroline (Teflaro): a new cephalosporin.
Belavic JM
Nurse Pract; 2011 Nov; 36(11):12-3. PubMed ID: 22008594
[No Abstract] [Full Text] [Related]
40. Doxycycline for community-acquired pneumonia.
Cunha BA
Clin Infect Dis; 2003 Sep; 37(6):870. PubMed ID: 12955665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
